Biopharmaceutical Excipient Manufacturing Market by Type of Biologics (Antibodies, Vaccines, Cell Therapies and Other Biologics), Type of Excipient (Carbohydrates, Polymers, Solubilizers / Surfactants, Polyols, Proteins / Amino Acids and Others, Company S
Description
Biopharmaceutical Excipient Manufacturing Market by Type of Biologics (Antibodies, Vaccines, Cell Therapies and Other Biologics), Type of Excipient (Carbohydrates, Polymers, Solubilizers / Surfactants, Polyols, Proteins / Amino Acids and Others, Company Size (Small, Mid-sized, Large / Very Large), Scale of Operation (Preclinical, Clinical and Commercial) and Key Geographies (North America, Europe, Asia Pacific, Latin America, MENA, and RoW): Industry Trends and Global Forecasts, 2022-2035
Over the years, the rising popularity of biologics has led to a paradigm shift in the healthcare industry. In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines and gene therapies), by the US FDA, have steadily risen. In fact, over 8,000 biological pharmaceutical products are currently under clinical investigation worldwide. Given the evident benefits of biologics over small molecule drugs (including high efficacy, target specificity and favorable safety profiles), the biopharmaceutical market is poised to witness continued and consistent growth over the next several years. However, biological therapeutics are inherently less stable than small molecules and, hence, more prone to degradation by several physical and chemical degradation mechanisms. Therefore, a variety of excipients, which are pharmacologically inert substances themselves, are used to stabilize biologics during the manufacturing process and storage. Furthermore, excipients play a critical role in biologics development by enhancing the solubility and bioavailability, controlling pH and tonicity of the active pharmaceutical ingredients (APIs). Additionally, biopharmaceutical excipients act as bulking agents, antioxidants or preservatives. As a result, the demand for biopharmaceutical excipients has grown considerably. However, for some of the biopharmaceutical excipients, such as lipids, the associated manufacturing processes are highly complex, capital-intensive and fraught with multiple challenges. Some of the major issues related to the production of GMP grade biopharmaceutical excipients include the need for specialized expertise, lack of facilities with the necessary infrastructure and capacity to produce the required quality of substances, as well as concerns related to storage, safety and efficacy.
Considering the technical and routine operations-related challenges, an increasing number of biologics developers are increasingly relying on biopharmaceutical excipient manufacturers. The benefits of engaging such third-party service providers are numerous; for instance, contracting a supplier for medical grade biopharmaceutical excipients enables sponsors to leverage specialty biopharmaceutical excipients (available with the manufacturers), access larger capacities and achieve greater operational flexibility. Presently, there are several contract manufacturers that claim to have the required capabilities to manufacture a variety of biopharmaceutical excipients, including lipids, lactose, trehalose, mannitol, succinate, Tween 20 and benzyl alcohol. These companies are increasingly focusing on the development of co-processed multifunctional biopharmaceutical excipients to improve the stability and effectiveness of novel biotherapeutics. It is worth highlighting that biopharmaceutical excipient manufacturers are actively trying to consolidate their presence in this field by entering into strategic alliances, enhance their respective manufacturing capabilities in order to meet the growing demand for excipients used in biologics. In fact, recently, a number of deals were inked between vaccine developers and biopharmaceutical excipient manufacturers in order to cater to the urgent need for lipids for the formers’ respective COVID-19 vaccines. With outsourcing being increasingly accepted as a viable and beneficial business model within this field, we anticipate the biopharmaceutical excipient manufacturing market to grow at a steady pace in the coming years.
SCOPE OF THE REPORT
The ‘Biopharmaceutical Excipient Manufacturing Market by Type of Biologics (Antibodies, Vaccines, Cell Therapies and Other Biologics), Type of Excipient (Carbohydrates, Polymers, Solubilizers / Surfactants, Polyols, Proteins / Amino Acids and Others, Company Size (Small, Mid-sized, Large / Very Large), Scale of Operation (Preclinical, Clinical and Commercial) and Key Geographies (North America, Europe, Asia Pacific, Latin America, MENA, and RoW): Industry Trends and Global Forecasts, 2022-2035’ report features an extensive study of companies engaged in manufacturing of biopharmaceutical excipients. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report features:
A detailed assessment of the current landscape of engaged in offering biopharmaceutical excipients, along with information on their year of establishment, company size (in terms of employee count), location of headquarters, location of manufacturing facilities, type of excipient (based on chemical composition (carbohydrates, polyols, polymers, proteins / amino acids, salts, lipids, and others), based on function (surfactants, stabilizers, tonicity modifiers, bulking agents, buffering agents, solubility enhancers, drug delivery system, chelators, antimicrobials, antioxidants and others), based on chemical structure (organic and inorganic)), scale of operation (preclinical, clinical and commercial), type of formulation (liquid or parenteral and solid), type of biologic (vaccines, proteins / peptides, cell therapies, antibodies and blood products) and global regulatory compliance (United States Pharmacopoeia / United States Pharmacopoeia-National Formulary, European Pharmacopoeia, Japanese Pharmacopoeia, British Pharmacopoeia, China Pharmacopoeia, American Chemical Society grade, Indian Pharmacopoeia, Food Chemical Codex and Taiwan FDA).
An in-depth competitiveness analysis of the biopharmaceutical excipient manufacturers, based on supplier power (in terms of years of experience), company competitiveness (type of excipient based on chemical composition, function, chemical structure, and based on scale of operation, type of formulation, type of biologic, global regulatory compliance) and number of manufacturing facilities.
Elaborate profiles of prominent players (shortlisted based on a proprietary criterion) engaged in this domain. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives), financial information (if available), details related to its biopharmaceutical excipients portfolio, manufacturing facilities, recent developments, and an informed future outlook.
An analysis of recent partnerships inked between stakeholders engaged in this domain, during the period 2016-2021, covering distribution agreements, acquisitions, supply agreements, product development agreements, asset acquisitions, research and development agreements, manufacturing agreements, service alliances and other related agreements.
A detailed analysis of the recent expansions undertaken by various biopharmaceutical excipient manufacturers, based on several relevant parameters, such as year of expansion, type of expansion (capacity expansion, facility expansion and new facility), company size (small, mid-sized, large and very large companies), location of headquarters, location of expanded facility, type of excipient, type of drug molecule, most active players (in terms of number of recent expansions) and geographical distribution (region-wise and country-wise).
An estimate of the global installed capacity for biopharmaceutical excipients taking into consideration the capacities of various biopharmaceutical excipient manufacturers, along with information on the distribution of available global biopharmaceutical excipient production capacity based on several relevant parameters, such as company size (small, mid-sized, large and very large companies), scale of operation (preclinical, clinical and commercial) and key geographical regions (North America, Europe, and Asia-Pacific).
One of the key objectives of the report was to evaluate the current opportunity and the future potential of the biopharmaceutical excipient manufacturing market, over the next 15 years. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] type of biologics (antibodies, vaccines, cell therapies and other biologics), [B] type of excipient (carbohydrates, polymers, solubilizers / surfactants, polyols, proteins / amino acids and others), [C] company size (small, mid-sized, large / very large), [D] scale of operation (preclinical, clinical and commercial) and [E] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA and rest of the world).
In order to account for future uncertainties in the market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews / surveys with experts in the area (academia, industry and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and segments. Where possible, the available data has been checked for accuracy from multiple sources of information.
The secondary sources of information include:
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
KEY QUESTIONS ANSWERED
Who are the key players engaged in biopharmaceutical excipient manufacturing?
Which global regions are considered as key hubs for biopharmaceutical excipient manufacturing?
What type of partnership models are commonly adopted by stakeholders in this industry?
What kind of expansion initiatives have been undertaken by biopharmaceutical excipient manufacturers?
What is current, global biopharmaceutical excipient manufacturing capacity of contract manufacturers?
How is the current and future market opportunity likely to be distributed across key market segments?
CHAPTER OUTLINES
Chapter 2 is an executive summary of the key insights captured during our research. It offers a high-level view on the likely evolution of the biopharmaceutical excipient manufacturing market in the short to mid-term, and long term.
Chapter 3 provides a general overview of the biopharmaceutical excipients. In addition, it includes information on their properties and classification, based on route of administration, chemical structure, function, ability to interfere with metabolization and efflux mechanisms. Further, it highlights various applications of biopharmaceutical excipients and their role in pharmaceutical and biopharmaceutical industry.
Chapter 4 provides an overview of the current biopharmaceutical excipients, along with information on their year of establishment, company size (in terms of employee count), location of headquarters, location of manufacturing facilities, type of excipient (based on chemical composition (carbohydrates, polyols, polymers, proteins / amino acids, salts, lipids, and others), based on function (surfactants, stabilizers, tonicity modifiers, bulking agents, buffering agents, solubility enhancers, drug delivery system, chelators, antimicrobials, antioxidants and others), based on chemical structure (organic and inorganic)), scale of operation (preclinical, clinical and commercial), type of formulation (liquid or parenteral and solid), type of biologic (vaccines, proteins / peptides, cell therapies, antibodies and blood products) and global regulatory compliance (United States Pharmacopoeia / United States Pharmacopoeia-National Formulary, European Pharmacopoeia, Japanese Pharmacopoeia, British Pharmacopoeia, China Pharmacopoeia, American Chemical Society grade, Indian Pharmacopoeia, Food Chemical Codex and Taiwan FDA).
Chapter 5 features a detailed competitiveness analysis of the biopharmaceutical excipient manufacturers, based on supplier power (in terms of years of experience), company competitiveness (type of excipient based on chemical composition, function, chemical structure, and based on scale of operation, type of formulation, type of biologic, global regulatory compliance) and number of manufacturing facilities.
Chapter 6 provides detailed profiles of prominent players (shortlisted based on a proprietary criterion) engaged in this domain. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives), financial information (if available), details related to its biopharmaceutical excipients portfolio, manufacturing facilities, recent developments, and an informed future outlook.
Chapter 7 features an analysis of the various collaborations and partnerships inked between stakeholders engaged in this domain, during the period 2016-2021, covering distribution agreements, acquisitions, supply agreements, product development agreements, asset acquisitions, research and development agreements, manufacturing agreements, service alliances and other related agreements.
Chapter 8 presents a detailed analysis of the recent expansions undertaken by various biopharmaceutical excipient manufacturers, based on several relevant parameters, such as year of expansion, type of expansion (capacity expansion, facility expansion and new facility), company size (small, mid-sized, large and very large companies), location of headquarters, location of expanded facility, type of excipient, type of drug molecule, most active players (in terms of number of recent expansions) and geographical distribution (region-wise and country-wise).
Chapter 9 features a comprehensive analysis of the global installed capacity for biopharmaceutical excipients taking into consideration the capacities of various biopharmaceutical excipient manufacturers, along with information on the distribution of available global biopharmaceutical excipient production capacity based on several relevant parameters, such as company size (small, mid-sized, large and very large companies), scale of operation (preclinical, clinical and commercial) and key geographical regions (North America, Europe, and Asia-Pacific).
Chapter 10 presents an insightful market forecast analysis, highlighting the likely growth of the biopharmaceutical excipient manufacturing market till the year 2035. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] type of biologic (antibodies, vaccines, cell therapies and other biologics), [B] type of excipient (carbohydrates, polymers, solubilizers / surfactants, polyols, proteins / amino acids and others), [C] company size (small, mid-sized, large / very large), [D] scale of operation (preclinical, clinical and commercial) and [E] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA and rest of the world).
Chapter 11 summarizes the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.
Chapter 12 provides the transcripts of interviews conducted with representatives from renowned organizations that are engaged in the biopharmaceutical excipient manufacturing domain.
Chapter 13 is an appendix, that provides tabulated data and numbers for all the figures included in the report.
Chapter 14 is an appendix that provides the list of companies and organizations that have been mentioned in the report.
LIST OF COMPANIES AND ORGANIZATIONS
The following companies and organizations have been mentioned in the report.
1. A&C
2. ABITEC
3. Aceto
4. Aditya Chemicals
5. Alfa Aesar
6. AMCM
7. AmpTec
8. ANGUS Chemical Company
9. Apothecon Pharmaceuticals
10. Asahi Kasei
11. Avanti Polar Lipids
12. Avantor
13. Azelis Americas
14. Barentz
15. BASF
16. BioNTech
17. BioSpectra
18. BOC Sciences
19. Brenntag
20. Cascade Chemistry
21. CG Chemikalien
22. Cole-Parmer
23. CordenPharma
24. CPI
25. Creative Biostructure
26. Crest Cellulose (Acquired by Roquette)
27. Croda
28. DFE Pharma
29. DKSH
30. DuPont
31. DURECT
32. Evonik
33. Finar
34. GELITA
35. Harro Höfliger Verpackungsmaschinen
36. Hawkins
37. Hopax Fine Chemicals
38. Hosokawa Micron Powder Systems
39. Hunan Er-Kang Pharmaceutical
40. IMCD
41. IMCoPharma
42. Indchem International
43. InnoCore Pharmaceuticals
44. International Flavors & Fragrances
45. InVitria
46. Itacel (Acquired by Roquette)
47. ITW Reagents (A division of PanReac AppliChem)
48. Kerry
49. Kirsch Pharma
50. Kuraray
51. Larodan
52. Lazuline Biotech
53. LeBaronBrown Specialities
54. LUCA AICell
55. MaaS Pharma Chemicals
56. MEGGLE
57. Merck KGaA
58. Mitushi Biopharma
59. Moderna
60. National Institute of Bioprocessing Research and Training
61. Nordmann, Rassmann
62. PCAS
63. Pfanstiehl
64. Pfizer
65. Quadra Chemicals
66. ReForm Biologics
67. Roquette
68. Shanghai Huamao Pharmaceutical
69. Sigachi
70. Spectrum Chemical Mfg.
71. SPI Pharma
72. Stanford University
73. TTY Biopharm
74. Univar Solutions
75. VAV Life Sciences
76. Wilshire Technologies
Please note that the publisher limits purchases by consulting clients to either Consulting Company Team License or Global Site License for Entire Company. Any other selections will not be fulfilled by this publisher.
Over the years, the rising popularity of biologics has led to a paradigm shift in the healthcare industry. In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines and gene therapies), by the US FDA, have steadily risen. In fact, over 8,000 biological pharmaceutical products are currently under clinical investigation worldwide. Given the evident benefits of biologics over small molecule drugs (including high efficacy, target specificity and favorable safety profiles), the biopharmaceutical market is poised to witness continued and consistent growth over the next several years. However, biological therapeutics are inherently less stable than small molecules and, hence, more prone to degradation by several physical and chemical degradation mechanisms. Therefore, a variety of excipients, which are pharmacologically inert substances themselves, are used to stabilize biologics during the manufacturing process and storage. Furthermore, excipients play a critical role in biologics development by enhancing the solubility and bioavailability, controlling pH and tonicity of the active pharmaceutical ingredients (APIs). Additionally, biopharmaceutical excipients act as bulking agents, antioxidants or preservatives. As a result, the demand for biopharmaceutical excipients has grown considerably. However, for some of the biopharmaceutical excipients, such as lipids, the associated manufacturing processes are highly complex, capital-intensive and fraught with multiple challenges. Some of the major issues related to the production of GMP grade biopharmaceutical excipients include the need for specialized expertise, lack of facilities with the necessary infrastructure and capacity to produce the required quality of substances, as well as concerns related to storage, safety and efficacy.
Considering the technical and routine operations-related challenges, an increasing number of biologics developers are increasingly relying on biopharmaceutical excipient manufacturers. The benefits of engaging such third-party service providers are numerous; for instance, contracting a supplier for medical grade biopharmaceutical excipients enables sponsors to leverage specialty biopharmaceutical excipients (available with the manufacturers), access larger capacities and achieve greater operational flexibility. Presently, there are several contract manufacturers that claim to have the required capabilities to manufacture a variety of biopharmaceutical excipients, including lipids, lactose, trehalose, mannitol, succinate, Tween 20 and benzyl alcohol. These companies are increasingly focusing on the development of co-processed multifunctional biopharmaceutical excipients to improve the stability and effectiveness of novel biotherapeutics. It is worth highlighting that biopharmaceutical excipient manufacturers are actively trying to consolidate their presence in this field by entering into strategic alliances, enhance their respective manufacturing capabilities in order to meet the growing demand for excipients used in biologics. In fact, recently, a number of deals were inked between vaccine developers and biopharmaceutical excipient manufacturers in order to cater to the urgent need for lipids for the formers’ respective COVID-19 vaccines. With outsourcing being increasingly accepted as a viable and beneficial business model within this field, we anticipate the biopharmaceutical excipient manufacturing market to grow at a steady pace in the coming years.
SCOPE OF THE REPORT
The ‘Biopharmaceutical Excipient Manufacturing Market by Type of Biologics (Antibodies, Vaccines, Cell Therapies and Other Biologics), Type of Excipient (Carbohydrates, Polymers, Solubilizers / Surfactants, Polyols, Proteins / Amino Acids and Others, Company Size (Small, Mid-sized, Large / Very Large), Scale of Operation (Preclinical, Clinical and Commercial) and Key Geographies (North America, Europe, Asia Pacific, Latin America, MENA, and RoW): Industry Trends and Global Forecasts, 2022-2035’ report features an extensive study of companies engaged in manufacturing of biopharmaceutical excipients. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report features:
A detailed assessment of the current landscape of engaged in offering biopharmaceutical excipients, along with information on their year of establishment, company size (in terms of employee count), location of headquarters, location of manufacturing facilities, type of excipient (based on chemical composition (carbohydrates, polyols, polymers, proteins / amino acids, salts, lipids, and others), based on function (surfactants, stabilizers, tonicity modifiers, bulking agents, buffering agents, solubility enhancers, drug delivery system, chelators, antimicrobials, antioxidants and others), based on chemical structure (organic and inorganic)), scale of operation (preclinical, clinical and commercial), type of formulation (liquid or parenteral and solid), type of biologic (vaccines, proteins / peptides, cell therapies, antibodies and blood products) and global regulatory compliance (United States Pharmacopoeia / United States Pharmacopoeia-National Formulary, European Pharmacopoeia, Japanese Pharmacopoeia, British Pharmacopoeia, China Pharmacopoeia, American Chemical Society grade, Indian Pharmacopoeia, Food Chemical Codex and Taiwan FDA).
An in-depth competitiveness analysis of the biopharmaceutical excipient manufacturers, based on supplier power (in terms of years of experience), company competitiveness (type of excipient based on chemical composition, function, chemical structure, and based on scale of operation, type of formulation, type of biologic, global regulatory compliance) and number of manufacturing facilities.
Elaborate profiles of prominent players (shortlisted based on a proprietary criterion) engaged in this domain. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives), financial information (if available), details related to its biopharmaceutical excipients portfolio, manufacturing facilities, recent developments, and an informed future outlook.
An analysis of recent partnerships inked between stakeholders engaged in this domain, during the period 2016-2021, covering distribution agreements, acquisitions, supply agreements, product development agreements, asset acquisitions, research and development agreements, manufacturing agreements, service alliances and other related agreements.
A detailed analysis of the recent expansions undertaken by various biopharmaceutical excipient manufacturers, based on several relevant parameters, such as year of expansion, type of expansion (capacity expansion, facility expansion and new facility), company size (small, mid-sized, large and very large companies), location of headquarters, location of expanded facility, type of excipient, type of drug molecule, most active players (in terms of number of recent expansions) and geographical distribution (region-wise and country-wise).
An estimate of the global installed capacity for biopharmaceutical excipients taking into consideration the capacities of various biopharmaceutical excipient manufacturers, along with information on the distribution of available global biopharmaceutical excipient production capacity based on several relevant parameters, such as company size (small, mid-sized, large and very large companies), scale of operation (preclinical, clinical and commercial) and key geographical regions (North America, Europe, and Asia-Pacific).
One of the key objectives of the report was to evaluate the current opportunity and the future potential of the biopharmaceutical excipient manufacturing market, over the next 15 years. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] type of biologics (antibodies, vaccines, cell therapies and other biologics), [B] type of excipient (carbohydrates, polymers, solubilizers / surfactants, polyols, proteins / amino acids and others), [C] company size (small, mid-sized, large / very large), [D] scale of operation (preclinical, clinical and commercial) and [E] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA and rest of the world).
In order to account for future uncertainties in the market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews / surveys with experts in the area (academia, industry and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and segments. Where possible, the available data has been checked for accuracy from multiple sources of information.
The secondary sources of information include:
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
KEY QUESTIONS ANSWERED
Who are the key players engaged in biopharmaceutical excipient manufacturing?
Which global regions are considered as key hubs for biopharmaceutical excipient manufacturing?
What type of partnership models are commonly adopted by stakeholders in this industry?
What kind of expansion initiatives have been undertaken by biopharmaceutical excipient manufacturers?
What is current, global biopharmaceutical excipient manufacturing capacity of contract manufacturers?
How is the current and future market opportunity likely to be distributed across key market segments?
CHAPTER OUTLINES
Chapter 2 is an executive summary of the key insights captured during our research. It offers a high-level view on the likely evolution of the biopharmaceutical excipient manufacturing market in the short to mid-term, and long term.
Chapter 3 provides a general overview of the biopharmaceutical excipients. In addition, it includes information on their properties and classification, based on route of administration, chemical structure, function, ability to interfere with metabolization and efflux mechanisms. Further, it highlights various applications of biopharmaceutical excipients and their role in pharmaceutical and biopharmaceutical industry.
Chapter 4 provides an overview of the current biopharmaceutical excipients, along with information on their year of establishment, company size (in terms of employee count), location of headquarters, location of manufacturing facilities, type of excipient (based on chemical composition (carbohydrates, polyols, polymers, proteins / amino acids, salts, lipids, and others), based on function (surfactants, stabilizers, tonicity modifiers, bulking agents, buffering agents, solubility enhancers, drug delivery system, chelators, antimicrobials, antioxidants and others), based on chemical structure (organic and inorganic)), scale of operation (preclinical, clinical and commercial), type of formulation (liquid or parenteral and solid), type of biologic (vaccines, proteins / peptides, cell therapies, antibodies and blood products) and global regulatory compliance (United States Pharmacopoeia / United States Pharmacopoeia-National Formulary, European Pharmacopoeia, Japanese Pharmacopoeia, British Pharmacopoeia, China Pharmacopoeia, American Chemical Society grade, Indian Pharmacopoeia, Food Chemical Codex and Taiwan FDA).
Chapter 5 features a detailed competitiveness analysis of the biopharmaceutical excipient manufacturers, based on supplier power (in terms of years of experience), company competitiveness (type of excipient based on chemical composition, function, chemical structure, and based on scale of operation, type of formulation, type of biologic, global regulatory compliance) and number of manufacturing facilities.
Chapter 6 provides detailed profiles of prominent players (shortlisted based on a proprietary criterion) engaged in this domain. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives), financial information (if available), details related to its biopharmaceutical excipients portfolio, manufacturing facilities, recent developments, and an informed future outlook.
Chapter 7 features an analysis of the various collaborations and partnerships inked between stakeholders engaged in this domain, during the period 2016-2021, covering distribution agreements, acquisitions, supply agreements, product development agreements, asset acquisitions, research and development agreements, manufacturing agreements, service alliances and other related agreements.
Chapter 8 presents a detailed analysis of the recent expansions undertaken by various biopharmaceutical excipient manufacturers, based on several relevant parameters, such as year of expansion, type of expansion (capacity expansion, facility expansion and new facility), company size (small, mid-sized, large and very large companies), location of headquarters, location of expanded facility, type of excipient, type of drug molecule, most active players (in terms of number of recent expansions) and geographical distribution (region-wise and country-wise).
Chapter 9 features a comprehensive analysis of the global installed capacity for biopharmaceutical excipients taking into consideration the capacities of various biopharmaceutical excipient manufacturers, along with information on the distribution of available global biopharmaceutical excipient production capacity based on several relevant parameters, such as company size (small, mid-sized, large and very large companies), scale of operation (preclinical, clinical and commercial) and key geographical regions (North America, Europe, and Asia-Pacific).
Chapter 10 presents an insightful market forecast analysis, highlighting the likely growth of the biopharmaceutical excipient manufacturing market till the year 2035. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] type of biologic (antibodies, vaccines, cell therapies and other biologics), [B] type of excipient (carbohydrates, polymers, solubilizers / surfactants, polyols, proteins / amino acids and others), [C] company size (small, mid-sized, large / very large), [D] scale of operation (preclinical, clinical and commercial) and [E] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA and rest of the world).
Chapter 11 summarizes the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.
Chapter 12 provides the transcripts of interviews conducted with representatives from renowned organizations that are engaged in the biopharmaceutical excipient manufacturing domain.
Chapter 13 is an appendix, that provides tabulated data and numbers for all the figures included in the report.
Chapter 14 is an appendix that provides the list of companies and organizations that have been mentioned in the report.
LIST OF COMPANIES AND ORGANIZATIONS
The following companies and organizations have been mentioned in the report.
1. A&C
2. ABITEC
3. Aceto
4. Aditya Chemicals
5. Alfa Aesar
6. AMCM
7. AmpTec
8. ANGUS Chemical Company
9. Apothecon Pharmaceuticals
10. Asahi Kasei
11. Avanti Polar Lipids
12. Avantor
13. Azelis Americas
14. Barentz
15. BASF
16. BioNTech
17. BioSpectra
18. BOC Sciences
19. Brenntag
20. Cascade Chemistry
21. CG Chemikalien
22. Cole-Parmer
23. CordenPharma
24. CPI
25. Creative Biostructure
26. Crest Cellulose (Acquired by Roquette)
27. Croda
28. DFE Pharma
29. DKSH
30. DuPont
31. DURECT
32. Evonik
33. Finar
34. GELITA
35. Harro Höfliger Verpackungsmaschinen
36. Hawkins
37. Hopax Fine Chemicals
38. Hosokawa Micron Powder Systems
39. Hunan Er-Kang Pharmaceutical
40. IMCD
41. IMCoPharma
42. Indchem International
43. InnoCore Pharmaceuticals
44. International Flavors & Fragrances
45. InVitria
46. Itacel (Acquired by Roquette)
47. ITW Reagents (A division of PanReac AppliChem)
48. Kerry
49. Kirsch Pharma
50. Kuraray
51. Larodan
52. Lazuline Biotech
53. LeBaronBrown Specialities
54. LUCA AICell
55. MaaS Pharma Chemicals
56. MEGGLE
57. Merck KGaA
58. Mitushi Biopharma
59. Moderna
60. National Institute of Bioprocessing Research and Training
61. Nordmann, Rassmann
62. PCAS
63. Pfanstiehl
64. Pfizer
65. Quadra Chemicals
66. ReForm Biologics
67. Roquette
68. Shanghai Huamao Pharmaceutical
69. Sigachi
70. Spectrum Chemical Mfg.
71. SPI Pharma
72. Stanford University
73. TTY Biopharm
74. Univar Solutions
75. VAV Life Sciences
76. Wilshire Technologies
Please note that the publisher limits purchases by consulting clients to either Consulting Company Team License or Global Site License for Entire Company. Any other selections will not be fulfilled by this publisher.
Table of Contents
175 Pages
- 1. PREFACE
- 1.1. Scope of the Report
- 1.2. Research Methodology
- 1.3. Key Questions Answered
- 1.4. Chapter Outlines
- 2. EXECUTIVE SUMMARY
- 3. INTRODUCTION
- 3.1. Chapter Overview
- 3.2. Biopharmaceutical Excipients
- 3.3. Properties of Ideal Excipients
- 3.4. Classification of Biopharmaceutical Excipients
- 3.4.1. Classification based on Route of Administration
- 3.4.2. Classification of Excipients based on Structure
- 3.4.3. Classification of Excipients based on Function
- 3.4.4. Classification based on Ability to Interfere with Metabolization and Efflux
- Mechanisms
- 3.5. Applications of Biopharmaceutical Excipients
- 3.6. Regulatory Scenario
- 3.7. Concluding Remarks
- 4. MARKET LANDSCAPE
- 4.1. Chapter Overview
- 4.2. Biopharmaceutical Excipient Manufacturers: Overall Market Landscape
- 4.2.1. Analysis by Year of Establishment
- 4.2.2. Analysis by Company Size
- 4.2.3. Analysis by Location of Headquarters
- 4.2.4. Analysis by Location of Biopharmaceutical Excipient Manufacturing Facilities
- 4.2.5. Analysis by Type of Excipient based on Chemical Composition
- 4.2.6. Analysis by Type of Excipient based on Function
- 4.2.7. Analysis by Type of Excipient based on Chemical Structure
- 4.2.8. Analysis by Scale of Operation
- 4.2.9. Analysis by Type of Formulation
- 4.2.10. Analysis by Type of Biologic
- 4.2.11. Analysis by Global Regulatory Compliance
- 5. COMPANY COMPETITIVENESS ANALYSIS
- 5.1. Chapter Overview
- 5.2. Assumptions and Key Parameters
- 5.3. Methodology
- 5.4. Biopharmaceutical Excipient Manufacturers: Company Competitiveness Analysis
- 5.4.1. Company Competitiveness Analysis: Small Companies
- 5.4.2. Company Competitiveness Analysis: Mid-Sized Companies
- 5.4.3. Company Competitiveness Analysis: Large Companies
- 5.4.4. Company Competitiveness Analysis: Very Large Companies
- 6. COMPANY PROFILES: BIOPHARMACEUTICAL EXCIPIENT
- MANUFACTURERS
- 6.1. Chapter Overview
- 6.2. ABITEC
- 6.2.1. Company Overview
- 6.2.2. Biopharmaceutical Excipient Offerings
- 6.2.3. Manufacturing Facilities
- 6.2.4. Recent Developments and Future Outlook
- 6.3. Avantor
- 6.3.1. Company Overview
- 6.3.2. Financial Information
- 6.3.3. Biopharmaceutical Excipient Offerings
- 6.3.4. Manufacturing Facilities
- 6.3.5. Recent Developments and Future Outlook
- 6.4. BASF Pharma
- 6.4.1. Company Overview
- 6.4.2. Financial Information
- 6.4.3. Biopharmaceutical Excipient Offerings
- 6.4.4. Manufacturing Facilities
- 6.4.5. Recent Developments and Future Outlook
- 6.5. Corden Pharma
- 6.5.1. Company Overview
- 6.5.2. Biopharmaceutical Excipient Service Offerings
- 6.5.3. Manufacturing Facilities
- 6.5.4. Recent Developments and Future Outlook
- 6.6. DFE Pharma
- 6.6.1. Company Overview
- 6.6.2. Biopharmaceutical Excipient Offerings
- 6.6.3. Manufacturing Facilities
- 6.6.4. Recent Developments and Future Outlook
- 6.7. Evonik
- 6.7.1. Company Overview
- 6.7.2. Financial Information
- 6.7.3. Biopharmaceutical Excipient Offerings
- 6.7.4. Manufacturing Facilities
- 6.7.5. Recent Developments and Future Outlook
- 6.8. Kirsch Pharma
- 6.8.1. Company Overview
- 6.8.2. Biopharmaceutical Excipient Offerings
- 6.8.3. Manufacturing Facilities
- 6.8.4. Recent Developments and Future Outlook
- 6.9. Merck KGaA
- 6.9.1. Company Overview
- 6.9.2. Financial Information
- 6.9.3. Biopharmaceutical Excipient Offerings
- 6.9.4. Manufacturing Facilities
- 6.9.5. Recent Developments and Future Outlook
- 6.10. Pfanstiehl
- 6.10.1. Company Overview
- 6.10.2. Biopharmaceutical Excipient Offerings
- 6.10.3. Manufacturing Facilities
- 6.10.4. Recent Developments and Future Outlook
- 6.11. Roquette
- 6.11.1. Company Overview
- 6.11.2. Biopharmaceutical Excipient Offerings
- 6.11.3. Manufacturing Facilities
- 6.11.4. Recent Developments and Future Outlook
- 6.12. Spectrum Chemical Manufacturing
- 6.12.1. Company Overview
- 6.12.2. Biopharmaceutical Excipient Offerings
- 6.12.3. Manufacturing Facilities
- 6.12.4. Recent Developments and Future Outlook
- 6.13. SPI Pharma
- 6.13.1. Company Overview
- 6.13.2. Biopharmaceutical Excipient Offerings
- 6.13.3. Manufacturing Facilities
- 6.13.4. Recent Developments and Future Outlook
- 7. PARTNERSHIPS AND COLLABORATIONS
- 7.1. Chapter Overview
- 7.2. Partnership Models
- 7.3. Biopharmaceutical Excipients Manufacturing Market: Partnerships and Collaborations
- 7.3.1. Analysis by Year of Partnership
- 7.3.2. Analysis by Type of Partnership
- 7.3.3. Analysis by Year and Type of Partnership
- 7.3.4. Analysis by Type of Excipient
- 7.3.5. Analysis by Type of Drug Molecule
- 7.3.5. Most Active Players: Analysis by Number of Partnerships
- 7.3.6. Analysis by Geography
- 7.3.6.1. Intercontinental and Intracontinental Deals
- 7.3.6.2. International and Local Deals
- 8. RECENT EXPANSIONS
- 8.1. Chapter Overview
- 8.2. Biopharmaceutical Excipient Manufacturing Market: Recent Expansions
- 8.2.1. Analysis by Year of Expansion
- 8.2.2. Analysis by Type of Expansion
- 8.2.3. Analysis by Company Size and Location of Headquarters
- 8.2.4. Analysis by Location of Expanded Facility
- 8.2.5. Analysis by Type of Excipient
- 8.2.6. Analysis by Type of Drug Molecule
- 8.2.7. Most Active Players: Analysis by Number of Recent Expansions
- 8.2.8. Geographical Analysis
- 8.2.8.1. Region-wise Distribution
- 8.2.8.2. Country-wise Distribution
- 9. CAPACITY ANALYSIS
- 9.1. Chapter Overview
- 9.2. Key Assumptions and Methodology
- 9.3. Biopharmaceutical Excipient Manufacturing: Installed Global Capacity
- 9.3.1. Analysis by Company Size
- 9.3.2. Analysis by Scale of Operation
- 9.3.3. Analysis by Location of Manufacturing Facility
- 9.4. Concluding Remarks
- 10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
- 10.1. Chapter Overview
- 10.2. Forecast Methodology and Key Assumptions
- 10.3. Global Biopharmaceutical Excipient Manufacturing Market, 2022-2035
- 10.4. Biopharmaceutical Excipient Manufacturing Market: Distribution by Type of Biologic, 2022 and 2035
- 10.5. Biopharmaceutical Excipient Manufacturing Market: Distribution by Type of Excipient, 2022 and 2035
- 10.6. Biopharmaceutical Excipient Manufacturing Market: Distribution by Company Size, 2022 and 2035
- 10.7. Biopharmaceutical Excipient Manufacturing Market: Distribution by Scale of Operation, 2022 and 2035
- 10.8. Biopharmaceutical Excipient Manufacturing Market: Distribution by Region, 2022 and 2035
- 10.8.1. Biopharmaceutical Excipient Manufacturing Market in North America, 2022-2035
- 10.8.2. Biopharmaceutical Excipient Manufacturing Market in Europe, 2022-2035
- 10.8.3. Biopharmaceutical Excipient Manufacturing Market in Asia Pacific, 2022-2035
- 10.8.4. Biopharmaceutical Excipient Manufacturing Market in Latin America, 2022-2035
- 10.8.5. Biopharmaceutical Excipient Manufacturing Market in MENA, 2022-2035
- 10.8.6. Biopharmaceutical Excipient Manufacturing Market in Rest of the World, 2022-2035
- 11. CONCLUDING REMARKS
- 12. EXECUTIVE INSIGHTS
- 12.1. Chapter Overview
- 12.2. DFE Pharma
- 12.2.1. Company Snapshot
- 12.2.2. Interview Transcript: Jeannette M. Wetzel, Biopharma Sales Director
- 13. APPENDIX 1: TABULATED DATA
- 14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
- LIST OF FIGURES
- Figure 2.1 Executive Summary: Market Forecast
- Figure 2.1 Executive Summary: Overall Market Landscape
- Figure 2.2 Executive Summary: Partnerships and Collaborations
- Figure 2.3 Executive Summary: Recent Expansions
- Figure 2.4 Executive Summary: Capacity Analysis
- Figure 2.5 Executive Summary: Market Forecast
- Figure 3.1 Properties of an Ideal Excipient
- Figure 3.2 Classification of Biopharmaceutical Excipients based on Ability to Interfere with Metabolization and Efflux Mechanisms
- Figure 3.3 Applications of Biopharmaceutical Excipients
- Figure 4.1 Biopharmaceutical Excipient Manufacturers: Distribution by Year of Establishment
- Figure 4.2 Biopharmaceutical Excipient Manufacturers: Distribution by Company Size
- Figure 4.3 Biopharmaceutical Excipient Manufacturers: Distribution by Location of Headquarters (Region-wise)
- Figure 4.4 Biopharmaceutical Excipient Manufacturers: Distribution by Location of Headquarters (Country-wise)
- Figure 4.5 Biopharmaceutical Excipient Manufacturers: Distribution by Location of Headquarters and Company Size
- Figure 4.6 Biopharmaceutical Excipient Manufacturers: Distribution by Location of Biopharmaceutical Excipient Manufacturing Facilities (Region-wise)
- Figure 4.7 Biopharmaceutical Excipients Manufacturers: Distribution by Location of Biopharmaceutical Excipient Manufacturing Facilities (Country-wise)
- Figure 4.8 Biopharmaceutical Excipient Manufacturers: Distribution by Type of Excipient based on Chemical Composition
- Figure 4.9 Biopharmaceutical Excipient Manufacturers: Distribution by Type of Excipient based on Function
- Figure 4.10 Biopharmaceutical Excipient Manufacturers: Distribution by Type of Excipient based on Chemical Structure
- Figure 4.11 Biopharmaceutical Excipient Manufacturers: Distribution by Scale of Operation
- Figure 4.12 Biopharmaceutical Excipient Manufacturers: Distribution by Type of Formulation
- Figure 4.13 Biopharmaceutical Excipient Manufacturers: Distribution by Type of Biologic
- Figure 4.14 Biopharmaceutical Excipient Manufacturers: Distribution by Global Regulatory Compliance
- Figure 5.1 Company Competitiveness Analysis: Small Companies
- Figure 5.2 Company Competitiveness Analysis: Mid-sized Companies
- Figure 5.3 Company Competitiveness Analysis: Large Companies
- Figure 5.4 Company Competitiveness Analysis: Very Large Companies
- Figure 6.1 BASF Pharma: Annual Revenues, 2016-2021 (EUR Million)
- Figure 6.2 Evonik: Annual Revenues, 2016-2020 (EUR Million)
- Figure 6.3 Merck KGaA: Annual Revenues, 2016-2021 (EUR Million)
- Figure 7.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2016-2021
- Figure 7.2 Partnerships and Collaborations: Distribution by Type of Partnership
- Figure 7.3 Partnerships and Collaborations: Year-wise Trend by Type of Partnership
- Figure 7.4 Partnerships and Collaborations: Distribution by Type of Excipient
- Figure 7.5 Partnerships and Collaborations: Distribution by Type of Drug Molecule
- Figure 7.6 Partnerships and Collaborations: Year-Wise Trend of Partnerships by Type of Drug
- Molecule, 2016-2021
- Figure 7.7 Most Active Players: Distribution by Number of Partnerships
- Figure 7.8 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
- Figure 7.9 Partnerships and Collaborations: International and Local Distribution
- Figure 8.1 Recent Expansions: Cumulative Year-wise Trend, 2016-2021
- Figure 8.2 Recent Expansions: Distribution by Type of Expansion
- Figure 8.3 Recent Expansions: Distribution by Company Size and Location of Headquarters
- Figure 8.4 Recent Expansions: Distribution by Location of Expanded Facility
- Figure 8.5 Recent Expansions: Distribution by Location of Facility Expanded and
- Type of Expansion
- Figure 8.6 Recent Expansions: Distribution by Type of Excipient
- Figure 8.7 Recent Expansions: Distribution by Type of Drug Molecule
- Figure 8.8 Most Active Players: Distribution by Number of Recent Expansions
- Figure 8.9 Recent Expansions: Year-wise Distribution by Geography
- Figure 8.10 Recent Expansions: Country-wise Distribution
- Figure 9.1 Biopharmaceutical Excipient Manufacturing Installed Global Capacity: Distribution by Range of Installed Capacity
- Figure 9.2 Biopharmaceutical Excipient Manufacturing Installed Global Capacity: Distribution by Company Size
- Figure 9.3 Biopharmaceutical Excipient Manufacturing Installed Global Capacity: Distribution by Scale of Operation
- Figure 9.4 Biopharmaceutical Excipient Manufacturing Installed Global Capacity: Distribution by Location of Manufacturing Facility (Continent-wise)
- Figure 9.5 Biopharmaceutical Excipient Manufacturing Installed Global Capacity: Distribution by Location of Manufacturing Facility (Country-wise)
- Figure 10.1 Global Biopharmaceutical Excipient Manufacturing Market, 2022-2035 (USD Billion)
- Figure 10.2 Biopharmaceutical Excipient Manufacturing Market: Likely Growth Scenarios
- Figure 10.3 Biopharmaceutical Excipient Manufacturing Market: Distribution by Type of Biologic, 2022 and 2035 (USD Billion)
- Figure 10.4 Biopharmaceutical Excipient Manufacturing Market: Distribution by Type of Excipient, 2022 and 2035 (USD Billion)
- Figure 10.5 Biopharmaceutical Excipient Manufacturing Market: Distribution by Company Size, 2022 and 2035 (USD Billion)
- Figure 10.6 Biopharmaceutical Excipient Manufacturing Market: Distribution by Scale of Operation, 2022 and 2035 (USD Billion)
- Figure 10.7 Biopharmaceutical Excipient Manufacturing Market: Distribution by Region, 2022 and 2035(USD Billion)
- Figure 10.8 Biopharmaceutical Excipient Manufacturing Market in North America, 2022-2035 (USD Billion)
- Figure 10.9 Biopharmaceutical Excipient Manufacturing Market in Europe, 2022-2035 (USD Billion)
- Figure 10.10 Biopharmaceutical Excipient Manufacturing Market in Asia Pacific, 2022-2035 (USD Billion)
- Figure 10.11 Biopharmaceutical Excipient Manufacturing Market in Latin America, 2022-2035 (USD Billion)
- Figure 10.12 Biopharmaceutical Excipient Manufacturing Market in MENA, 2022-2035 (USD Billion)
- Figure 10.13 Biopharmaceutical Excipient Manufacturing Market in Rest of the World, 2022-2035 (USD Billion)
- Figure 11.1 Concluding Remarks: Overall Market Landscape
- Figure 11.2 Concluding Remarks: Partnerships and Collaborations
- Figure 11.3 Concluding Remarks: Recent Expansions
- Figure 11.4 Concluding Remarks: Capacity Analysis
- Figure 11.5 Concluding Remarks: Market Forecast
- LIST OF TABLES
- Table 3.1 Classification of Biopharmaceutical Excipients based on Function
- Table 4.1 Biopharmaceutical Excipient Manufacturers: List of Companies
- Table 4.2 Biopharmaceutical Excipient Manufacturers: Information on Type of Excipient based on Chemical Composition and Function
- Table 4.3 Biopharmaceutical Excipient Manufacturers: Information on Scale of Operation, Type of Formulation, Type of Excipient (based on Chemical Structure), Type of Biologic and Global Regulatory Compliance
- Table 6.1 Leading Biopharmaceutical Excipient Manufacturers
- Table 6.2 ABITEC: Company Snapshot
- Table 6.3 ABITEC: Biopharmaceutical Excipient Offerings
- Table 6.4 ABITEC: Information on Manufacturing Facilities
- Table 6.5 ABITEC: Recent Developments and Future Outlook
- Table 6.6 Avantor: Company Snapshot
- Table 6.7 Avantor: Biopharmaceutical Excipient Offerings
- Table 6.8 Avantor: Information on Manufacturing Facilities
- Table 6.9 Avantor: Recent Developments and Future Outlook
- Table 6.10 BASF: Company Snapshot
- Table 6.11 BASF: Biopharmaceutical Excipient Offerings
- Table 6.12 BASF: Information on Manufacturing Facilities
- Table 6.13 BASF: Recent Developments and Future Outlook
- Table 6.14 Corden Pharma: Company Snapshot
- Table 6.15 Corden Pharma: Biopharmaceutical Excipient Offerings
- Table 6.16 Corden Pharma: Information on Manufacturing Facilities
- Table 6.17 Corden Pharma: Recent Developments and Future Outlook
- Table 6.18 DFE Pharma: Company Snapshot
- Table 6.19 DFE Pharma: Biopharmaceutical Excipient Offerings
- Table 6.20 DFE Pharma: Information on Manufacturing Facilities
- Table 6.21 DFE Pharma: Recent Developments and Future Outlook
- Table 6.22 Evonik: Company Snapshot
- Table 6.23 Evonik: Biopharmaceutical Excipient Offerings
- Table 6.24 Evonik: Information on Manufacturing Facilities
- Table 6.25 Evonik: Recent Developments and Future Outlook
- Table 6.26 Kirsch Pharma: Company Snapshot
- Table 6.27 Kirsch Pharma: Biopharmaceutical Excipient Offerings
- Table 6.28 Kirsch Pharma: Information on Manufacturing Facilities
- Table 6.29 Kirsch Pharma: Recent Developments and Future Outlook
- Table 6.30 Merck KGaA: Company Snapshot
- Table 6.31 Merck KGaA: Biopharmaceutical Excipient Offerings
- Table 6.32 Merck KGaA: Information on Manufacturing Facilities
- Table 6.33 Merck KGaA: Recent Developments and Future Outlook
- Table 6.34 Pfanstiehl: Company Snapshot
- Table 6.35 Pfanstiehl: Biopharmaceutical Excipient Offerings
- Table 6.36 Pfanstiehl: Information on Manufacturing Facilities
- Table 6.37 Pfanstiehl: Recent Developments and Future Outlook
- Table 6.38 Roquette: Company Snapshot
- Table 6.39 Roquette: Biopharmaceutical Excipient Offerings
- Table 6.40 Roquette: Information on Manufacturing Facilities
- Table 6.41 Roquette: Recent Developments and Future Outlook
- Table 6.42 Spectrum Chemical Manufacturing: Company Snapshot
- Table 6.43 Spectrum Chemical Manufacturing: Biopharmaceutical Excipient Offerings
- Table 6.44 Spectrum Chemical Manufacturing: Information on Manufacturing Facilities
- Table 6.45 SPI Pharma: Company Snapshot
- Table 6.46 SPI Pharma: Biopharmaceutical Excipient Offerings
- Table 6.47 SPI Pharma: Information on Manufacturing Facilities
- Table 6.48 SPI Pharma: Recent Developments and Future Outlook
- Table 7.1 Biopharmaceutical Excipient Manufacturers: List of Partnerships and Collaborations, 2016-2021
- Table 8.1 Biopharmaceutical Excipient Manufacturers: Recent Expansions, 2016-2021
- Table 9.1 Capacity Analysis: Information on Company Size of Biopharmaceutical Excipient Manufacturers
- Table 9.2 Capacity Analysis: Information on Average Capacity by Company Size
- Table 9.3 Biopharmaceutical Excipient Manufacturing Installed Global Capacity: Total Capacity by Company Size
- Table 12.1 DFE Pharma: Company Snapshot
- Table 13.1 Biopharmaceutical Excipient Manufacturers: Distribution by Year of Establishment
- Table 13.2 Biopharmaceutical Excipient Manufacturers: Distribution by Company Size
- Table 13.3 Biopharmaceutical Excipient Manufacturers: Distribution by Location of Headquarters (Region-wise)
- Table 13.4 Biopharmaceutical Excipient Manufacturers: Distribution by Location of Headquarters (Country-wise)
- Table 13.5 Biopharmaceutical Excipient Manufacturers: Distribution by Location of Headquarters and Company Size
- Table 13.6 Biopharmaceutical Excipient Manufacturers: Distribution by Location of Biopharmaceutical Excipient Manufacturing Facilities (Region-wise)
- Table 13.7 Biopharmaceutical Excipients Manufacturers: Distribution by Location of Biopharmaceutical Excipient Manufacturing Facilities (Country-wise)
- Table 13.8 Biopharmaceutical Excipient Manufacturers: Distribution by Type of Excipient based on Chemical Composition
- Table 13.9 Biopharmaceutical Excipient Manufacturers: Distribution by Type of Excipient based on Function
- Table 13.10 Biopharmaceutical Excipient Manufacturers: Distribution by Type of Excipient based on Chemical Structure
- Table 13.11 Biopharmaceutical Excipient Manufacturers: Distribution by Scale of Operation
- Table 13.12 Biopharmaceutical Excipient Manufacturers: Distribution by Type of Formulation
- Table 13.13 Biopharmaceutical Excipient Manufacturers: Distribution by Type of Biologic
- Table 13.14 Biopharmaceutical Excipient Manufacturers: Distribution by Global Regulatory Compliance
- Table 13.15 BASF Pharma: Annual Revenues, 2016-2021 (EUR Million)
- Table 13.16 Evonik: Annual Revenues, 2016-2020 (EUR Million)
- Table 13.17 Merck KGaA: Annual Revenues, 2016-2021 (EUR Million)
- Table 13.18 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2016-2021
- Table 13.19 Partnerships and Collaborations: Distribution by Type of Partnership
- Table 13.20 Partnerships and Collaborations: Year-wise Trend by Type of Partnership
- Table 13.21 Partnerships and Collaborations: Distribution by Type of Excipient
- Table 13.22 Partnerships and Collaborations: Distribution by Type of Drug Molecule
- Table 13.23 Partnerships and Collaborations: Year-Wise Trend of Partnerships by Type of Drug
- Molecule, 2016-2021
- Table 13.24 Most Active Players: Distribution by Number of Partnerships
- Table 13.25 Partnerships and Collaborations: Distribution by Intercontinental and Intracontinental Deals
- Table 13.26 Partnerships and Collaborations: Distribution by International and Local Deals
- Table 13.27 Recent Expansions: Cumulative Year-wise Trend, 2016-2021
- Table 13.28 Recent Expansions: Distribution by Type of Expansion
- Table 13.29 Recent Expansions: Distribution by Company Size and Location of Headquarters
- Table 13.30 Recent Expansions: Distribution by Location of Expanded Facility
- Table 13.31 Recent Expansions: Distribution by Location of Facility Expanded and Type of Expansion
- Table 13.32 Recent Expansions: Distribution by Type of Excipient
- Table 13.33 Recent Expansions: Distribution by Type of Drug Molecule
- Table 13.34 Most Active Players: Distribution by Number of Recent Expansions
- Table 13.35 Recent Expansions: Year-wise Distribution by Geography
- Table 13.36 Recent Expansions: Country-wise Distribution
- Table 13.37 Biopharmaceutical Excipient Manufacturing Installed Global Capacity: Distribution by Range of Installed Capacity
- Table 13.38 Biopharmaceutical Excipient Manufacturing Installed Global Capacity: Distribution by Company Size
- Table 13.39 Biopharmaceutical Excipient Manufacturing Installed Global Capacity: Distribution by Scale of Operation
- Table 13.40 Biopharmaceutical Excipient Manufacturing Installed Global Capacity: Distribution by Location of Manufacturing Facility (Continent-wise)
- Table 13.41 Biopharmaceutical Excipient Manufacturing Installed Global Capacity: Distribution by Location of Manufacturing Facility (Country-wise)
- Table 13.42 Global Biopharmaceutical Excipient Manufacturing Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
- Table 13.43 Biopharmaceutical Excipient Manufacturing Market: Distribution by Type of Biologic, 2022 and 2035 (USD Billion)
- Table 13.44 Biopharmaceutical Excipient Manufacturing Market: Distribution by Type of Excipient, 2022 and 2035 (USD Billion)
- Table 13.45 Biopharmaceutical Excipient Manufacturing Market: Distribution by Company Size, 2022 and 2035 (USD Billion)
- Table 13.46 Biopharmaceutical Excipient Manufacturing Market: Distribution by Scale of Operation, 2022 and 2035 (USD Billion)
- Table 13.47 Biopharmaceutical Excipient Manufacturing Market: Distribution by Region, Conservative, Base and Optimistic Scenarios, 2022 and 2035 (USD Billion)
- Table 13.48 Biopharmaceutical Excipient Manufacturing Market in North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
- Table 13.49 Biopharmaceutical Excipient Manufacturing Market in Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
- Table 13.50 Biopharmaceutical Excipient Manufacturing Market in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
- Table 13.51 Biopharmaceutical Excipient Manufacturing Market in Latin America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
- Table 13.52 Biopharmaceutical Excipient Manufacturing Market in MENA, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
- Table 13.53 Biopharmaceutical Excipient Manufacturing Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
